Multiplexed activation of endogenous genes by CRISPRa elicits potent anti-tumor immunity

[1]  J. Castle,et al.  Actively personalized vaccination trial for newly diagnosed glioblastoma , 2018, Nature.

[2]  Alyssa R. Richman,et al.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial , 2018, Nature.

[3]  Y. Kluger,et al.  Zero-preserving imputation of scRNA-seq data using low-rank approximation , 2018, bioRxiv.

[4]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[5]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[6]  Ö. Türeci,et al.  Personalized vaccines for cancer immunotherapy , 2018, Science.

[7]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[8]  R. Houot,et al.  Intratumoral immunotherapy: using the tumor as the remedy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[10]  Kathleen A. Marshall,et al.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial , 2017, The Lancet.

[11]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[12]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[13]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[14]  Elaine R. Mardis,et al.  Applications of Immunogenomics to Cancer , 2017, Cell.

[15]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[16]  Grace X. Y. Zheng,et al.  Massively parallel digital transcriptional profiling of single cells , 2016, Nature Communications.

[17]  Neville E Sanjana,et al.  Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening , 2016, Nature Protocols.

[18]  T. Schumacher,et al.  Neoantigen landscape dynamics during human melanoma–T cell interactions , 2016, Nature.

[19]  M. Vignali,et al.  T‐cell receptor profiling in cancer , 2015, Molecular oncology.

[20]  P. Campbell,et al.  Somatic mutation in cancer and normal cells , 2015, Science.

[21]  Trevor J Pugh,et al.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.

[22]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[23]  E. Komech,et al.  tcR: an R package for T cell receptor repertoire advanced data analysis , 2015, BMC Bioinformatics.

[24]  S. E. Barker,et al.  Long-term effect of gene therapy on Leber's congenital amaurosis. , 2015, The New England journal of medicine.

[25]  Mikhail Shugay,et al.  MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.

[26]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[27]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[28]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[29]  Ron Weiss,et al.  Highly-efficient Cas9-mediated transcriptional programming , 2014, Nature Methods.

[30]  Alexandro E. Trevino,et al.  Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex , 2014, Nature.

[31]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[32]  Ronald D. Vale,et al.  A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging , 2014, Cell.

[33]  J. Trueland.  Matter of life or death. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[34]  Simon Kasif,et al.  Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells , 2014, Cell.

[35]  J. Wolchok,et al.  Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy , 2014, Science Translational Medicine.

[36]  R. Bosselut,et al.  Gimap and T cells: A matter of life or death , 2014, European journal of immunology.

[37]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[38]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[39]  Laurens van der Maaten,et al.  Accelerating t-SNE using tree-based algorithms , 2014, J. Mach. Learn. Res..

[40]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[41]  G. Hartmann,et al.  Review Turning Tumors into Vaccines: Co-opting the Innate Immune System , 2022 .

[42]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[43]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[44]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[45]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[46]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[47]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[48]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[49]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[50]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[51]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[52]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[53]  K. High,et al.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges , 2011, Nature Reviews Genetics.

[54]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[55]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[56]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[57]  J. Rabinowitz,et al.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[59]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .

[60]  M. Nishimura,et al.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.

[61]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[62]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[63]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[64]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.